Cargando…

Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae

BACKGROUND: Nacubactam, a new β-lactamase inhibitor with antibacterial activity, is being developed as a single drug to be co-administered with cefepime or aztreonam. However, determining pharmacokinetics/pharmacodynamics (PK/PD) parameters in β-lactam/β-lactamase inhibitor combinations remains chal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Igarashi, Yuki, Takemura, Wataru, Liu, Xiaoxi, Kojima, Nana, Morita, Takumi, Chuang, Victor Tuan Giam, Enoki, Yuki, Taguchi, Kazuaki, Matsumoto, Kazuaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068424/ https://www.ncbi.nlm.nih.gov/pubmed/36775998 http://dx.doi.org/10.1093/jac/dkad033

Ejemplares similares

Pharmaceutical Integrity of Lyophilized Methemoglobin-Albumin Clusters after Reconstitution
por: Suzuki, Yuto, et al.
Publicado: (2023)

In Vivo Pharmacodynamics of β-Lactams/Nacubactam against Carbapenem-Resistant and/or Carbapenemase-Producing Enterobacter cloacae and Klebsiella pneumoniae in Murine Pneumonia Model
por: Hagihara, Mao, et al.
Publicado: (2021)

When Albumin Meets Liposomes: A Feasible Drug Carrier for Biomedical Applications
por: Taguchi, Kazuaki, et al.
Publicado: (2021)

Remdesivir for the treatment of coronavirus COVID-19: A meta-analysis of randomised controlled trials
por: Enoki, Yuki, et al.
Publicado: (2021)

Rational dosage regimens for cephalothin and cefazolin using pharmacokinetics and pharmacodynamics analysis in healthy horses
por: Kuroda, Taisuke, et al.
Publicado: (2021)

Neurotoxicity associated with colistin methanesulfonate treatment is enhanced by concomitant sevoflurane inhalation
por: Gotoda, Mai, et al.
Publicado: (2022)

A combination of 5/6‐nephrectomy and unilateral ureteral obstruction model accelerates progression of remote organ fibrosis in chronic kidney disease
por: Homma, Kyoka, et al.
Publicado: (2023)

Safety of linezolid in patients with decreased renal function and trough monitoring: a systematic review and meta-analysis
por: Liu, Xiaoxi, et al.
Publicado: (2022)

Asymmetric Total Syntheses of Both Enantiomers of Plymuthipyranone B and Its Unnatural Analogues: Evaluation of anti-MRSA Activity and Its Chiral Discrimination
por: Moriyama, Mizuki, et al.
Publicado: (2021)

Efficacy of surgical skin preparation with chlorhexidine in alcohol according to the concentration required to prevent surgical site infection: meta-analysis
por: Hasegawa, Tatsuki, et al.
Publicado: (2022)

Concentration-Dependent Activity of Pazufloxacin against Pseudomonas aeruginosa: An In Vivo Pharmacokinetic/Pharmacodynamic Study
por: Umezaki, Yasuhiro, et al.
Publicado: (2022)

Liposomal Artificial Red Blood Cell-Based Carbon Monoxide Donor Is a Potent Renoprotectant against Cisplatin-Induced Acute Kidney Injury
por: Taguchi, Kazuaki, et al.
Publicado: (2021)

The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing
por: Tsutsuura, Moeko, et al.
Publicado: (2021)

1287. Pharmacokinetics, Safety, and Tolerability of Nacubactam after Single Coadministration with β-Lactams in Japanese Healthy Subjects
por: Asano, Masayo, et al.
Publicado: (2020)

Population Pharmacokinetic Analysis and Dosing Optimization of Prophylactic Fluconazole in Japanese Patients with Hematological Malignancy
por: Sakamoto, Yasutaka, et al.
Publicado: (2021)

698. Nacubactam Inhibits Class A β-lactamases
por: Barnes, Melissa D, et al.
Publicado: (2018)

The G protein‐coupled receptor ligand apelin‐13 ameliorates skeletal muscle atrophy induced by chronic kidney disease
por: Enoki, Yuki, et al.
Publicado: (2022)

Efficacy and Safety of Daptomycin versus Vancomycin for Bacteremia Caused by Methicillin-Resistant Staphylococcus aureus with Vancomycin Minimum Inhibitory Concentration > 1 µg/mL: A Systematic Review and Meta-Analysis
por: Samura, Masaru, et al.
Publicado: (2022)

628. Pharmacokinetics, Safety and Tolerability of Co-administration of Nacubactam and β-lactams after Multiple Doses in Japanese Healthy Subjects
por: Sato, Hiroki, et al.
Publicado: (2021)

Analysis of adverse drug events in pulmonary Mycobacterium avium complex disease using spontaneous reporting system
por: Ozawa, Takuya, et al.
Publicado: (2022)

Ca-EDTA restores the activity of ceftazidime-avibactam or aztreonam against carbapenemase-producing Klebsiellapneumoniae infections
por: Wannigama, Dhammika Leshan, et al.
Publicado: (2023)

Benzbromarone Attenuates Oxidative Stress in Angiotensin II- and Salt-Induced Hypertensive Model Rats
por: Muraya, Nanako, et al.
Publicado: (2018)

Species Distribution of Candidemia and Their Susceptibility in a Single Japanese University Hospital: Prior Micafungin Use Affects the Appearance of Candida parapsilosis and Elevation of Micafungin MICs in Non-parapsilosis Candida Species
por: Sakamoto, Yasutaka, et al.
Publicado: (2021)

In vitro antimicrobial effects of aztreonam, colistin, and the 3-drug combination of aztreonam, ceftazidime and amikacin on metallo-β-lactamase-producing Pseudomonas aeruginosa
por: Oie, Shigeharu, et al.
Publicado: (2009)

Safety and Pharmacokinetic Characterization of Nacubactam, a Novel β-Lactamase Inhibitor, Alone and in Combination with Meropenem, in Healthy Volunteers
por: Mallalieu, Navita L., et al.
Publicado: (2020)

Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections
por: Matsumoto, Kazuaki, et al.
Publicado: (2016)

Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions
por: Minayoshi, Yuki, et al.
Publicado: (2018)

Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era
por: Bianco, Gabriele, et al.
Publicado: (2022)

Long chain fatty acids alter the interactive binding of ligands to the two principal drug binding sites of human serum albumin
por: Yamasaki, Keishi, et al.
Publicado: (2017)

Identification of Risk Factors for Daptomycin-Associated Creatine Phosphokinase Elevation and Development of a Risk Prediction Model for Incidence Probability
por: Samura, Masaru, et al.
Publicado: (2021)

In Vitro Susceptibility of Aztreonam-Vaborbactam, Aztreonam-Relebactam and Aztreonam-Avibactam Associations against Metallo-β-Lactamase-Producing Gram-Negative Bacteria
por: Emeraud, Cécile, et al.
Publicado: (2023)

Analysis of the Binding of Aripiprazole to Human Serum Albumin: The Importance of a Chloro-Group in the Chemical Structure
por: Sakurama, Keiki, et al.
Publicado: (2018)

1359. Activity of Meropenem/Nacubactam Combination Against Gram-Negative Clinical Isolates: ROSCO Global Surveillance 2017
por: Okujava, Rusudan, et al.
Publicado: (2018)

2136. In Vitro Activity of Nacubactam (OP0595) Combined with Cefepime against Carbapenem-resistant Enterobacterales Isolated in Japan
por: Yanagihara, Katsunori, et al.
Publicado: (2023)

Interactions of Polymyxin B in Combination with Aztreonam, Minocycline, Meropenem, and Rifampin against Escherichia coli Producing NDM and OXA-48-Group Carbapenemases
por: Olsson, Anna, et al.
Publicado: (2021)

Semimechanistic Pharmacodynamic Modeling of Aztreonam‐Avibactam Combination to Understand Its Antimicrobial Activity Against Multidrug‐Resistant Gram‐Negative Bacteria
por: Chauzy, Alexia, et al.
Publicado: (2019)

A modified barrier enclosure to prevent viral aerosol transmission during endotracheal intubation and extubation of patients with coronavirus disease
por: Kojima, Yuki, et al.
Publicado: (2020)

Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019–2021)
por: Sader, Helio S, et al.
Publicado: (2023)

2149. In vitro Activity of Aztreonam-avibactam and Comparator Agents Against Carbapenem-Resistant Enterobacterales With and Without Carbapenemases, ATLAS Global Surveillance Program, 2017–2021
por: Wise, Mark G, et al.
Publicado: (2023)

Evaluation of Pharmacodynamic Interactions Between Telavancin and Aztreonam or Piperacillin/Tazobactam Against Pseudomonas aeruginosa, Escherichia coli and Methicillin-Resistant Staphylococcus aureus
por: Yim, Juwon, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_e32jbd5n5k43cgoudioqfsca9d